悦康药业(688658.SH)：拟发行H股

Core Viewpoint - The company, Yuyuan Pharmaceutical (688658.SH), plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its competitive edge and international brand image while diversifying its financing channels [1] Group 1: Company Strategy - The company aims to improve its overall competitiveness and international brand image through the issuance of H-shares [1] - The decision is in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1] - The company will consider the interests of existing shareholders and the conditions of domestic and international capital markets when selecting the timing for the issuance [1] Group 2: Regulatory Compliance - The issuance and listing will comply with the "Trial Measures for the Administration of the Issuance of Securities and Listing by Domestic Enterprises Overseas" and the listing rules of the Hong Kong Stock Exchange [1] - The company plans to complete the issuance within 24 months from the approval of the shareholders' meeting or within an extended period if agreed upon [1]